Not Yet Recruiting PHASE2 INTERVENTIONAL 3-arm NCT06363552

A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer

A Study to Evaluate the Preliminary Safety and Efficacy of SC0191 as Single Agent or in Combination With Bevacizumab or 5-FU/LV in Advanced Colorectal Cancer

Sponsor: Tianshu Liu

Conditions Metastatic Colorectal Cancer

Interventions SC0191 SC0191 + 5-FU/LV SC0191 + Bevacizumab

Updated 3 times since 2024 Last updated: Apr 9, 2024 Started: May 31, 2024 Primary completion: Apr 30, 2025 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Metastatic Colorectal Cancer and is currently actively recruiting participants. Tianshu Liu leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tianshu Liu

Data source: Shanghai Zhongshan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China